WO2009118737A2 - Diagnosis of periodic breathing - Google Patents
Diagnosis of periodic breathing Download PDFInfo
- Publication number
- WO2009118737A2 WO2009118737A2 PCT/IL2009/000337 IL2009000337W WO2009118737A2 WO 2009118737 A2 WO2009118737 A2 WO 2009118737A2 IL 2009000337 W IL2009000337 W IL 2009000337W WO 2009118737 A2 WO2009118737 A2 WO 2009118737A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- signal
- patient
- time shifts
- features
- cycle length
- Prior art date
Links
- 230000029058 respiratory gaseous exchange Effects 0.000 title claims abstract description 64
- 238000003745 diagnosis Methods 0.000 title claims abstract description 17
- 230000000737 periodic effect Effects 0.000 title description 26
- 238000000034 method Methods 0.000 claims abstract description 74
- 208000008784 apnea Diseases 0.000 claims abstract description 44
- 230000006870 function Effects 0.000 claims description 50
- 206010019280 Heart failures Diseases 0.000 claims description 34
- 238000012544 monitoring process Methods 0.000 claims description 20
- 239000008280 blood Substances 0.000 claims description 18
- 210000004369 blood Anatomy 0.000 claims description 18
- 238000012545 processing Methods 0.000 claims description 18
- 208000003417 Central Sleep Apnea Diseases 0.000 claims description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 239000001301 oxygen Substances 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 12
- 208000001797 obstructive sleep apnea Diseases 0.000 claims description 10
- 230000001186 cumulative effect Effects 0.000 claims description 7
- 230000007958 sleep Effects 0.000 description 37
- 230000009467 reduction Effects 0.000 description 20
- 230000000241 respiratory effect Effects 0.000 description 18
- 238000005259 measurement Methods 0.000 description 12
- 238000007781 pre-processing Methods 0.000 description 11
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 10
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 10
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 10
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 10
- 230000033001 locomotion Effects 0.000 description 9
- 238000004393 prognosis Methods 0.000 description 9
- 206010021079 Hypopnoea Diseases 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000002802 cardiorespiratory effect Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000000414 obstructive effect Effects 0.000 description 6
- 238000002106 pulse oximetry Methods 0.000 description 6
- 201000002859 sleep apnea Diseases 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 206010008501 Cheyne-Stokes respiration Diseases 0.000 description 4
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 4
- 206010047289 Ventricular extrasystoles Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000037007 arousal Effects 0.000 description 4
- 206010003119 arrhythmia Diseases 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000036387 respiratory rate Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 206010015856 Extrasystoles Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000000283 vasomotion Effects 0.000 description 3
- 206010062519 Poor quality sleep Diseases 0.000 description 2
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 2
- 208000019269 advanced heart failure Diseases 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 230000000739 chaotic effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108010064719 Oxyhemoglobins Proteins 0.000 description 1
- 238000012952 Resampling Methods 0.000 description 1
- 208000004301 Sinus Arrhythmia Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000020020 complex sleep apnea Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 208000000122 hyperventilation Diseases 0.000 description 1
- 230000000870 hyperventilation Effects 0.000 description 1
- 238000012623 in vivo measurement Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 201000006646 mixed sleep apnea Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 238000002496 oximetry Methods 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 238000013186 photoplethysmography Methods 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000001013 sinoatrial node Anatomy 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 238000004018 waxing Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
- A61B5/0816—Measuring devices for examining respiratory frequency
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4806—Sleep evaluation
- A61B5/4818—Sleep apnoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/024—Detecting, measuring or recording pulse rate or heart rate
- A61B5/02416—Detecting, measuring or recording pulse rate or heart rate using photoplethysmograph signals, e.g. generated by infrared radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7239—Details of waveform analysis using differentiation including higher order derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7253—Details of waveform analysis characterised by using transforms
- A61B5/726—Details of waveform analysis characterised by using transforms using Wavelet transforms
Definitions
- the present invention in some embodiments thereof, relates to physiological monitoring and, more particularly, but not exclusively, to the diagnosis of periodic breathing.
- Sleep apneas commonly occur in conjunction with a variety of cardiorespiratory disorders.
- the relationship between sleep apnea and heart failure, for example, is surveyed by Bradley et al. in two articles entitled “Sleep Apnea and Heart Failure,” including “Part I: Obstructive Sleep Apnea,” Circulation 107, pages 1671-1678 (2003), and “Part II: Central Sleep Apnea,” Circulation 107, pages 1822-1826 (2003), which are incorporated herein by reference.
- the authors define "apnea” as a cessation of airflow for more than 10 sec.
- hypopnea is a reduction in but not complete cessation of airflow to less than 50% of normal, usually in association with a reduction in oxyhemoglobin saturation (commonly referred to as “desaturation").
- CSA Central sleep apnea
- Cheyne-Stokes respiration which is a form of periodic breathing in which central apneas and hypopneas alternate with periods of hyperventilation, with a waxing-waning pattern of tidal volume.
- CSA is believed to arise as the result of heart failure, though obstructive sleep apnea (OSA) may also occur in heart failure patients.
- OSA obstructive sleep apnea
- Both OSA and CSA increase the strain on the cardiovascular system and thus worsen the prognosis of the heart failure patient. In some cases, both types of apneas may occur in the same patient, even at the same time (superposition). Classifying respiratory events as central or obstructive is considered to be a critical point, since treatment may differ according to the type of events, as pointed out by Pepin et al. in "Cheyne-Stokes Respiration with Central Sleep Apnea in Chronic Heart Failure: Proposals for a Diagnostic and Therapeutic Strategy," Sleep Medicine Reviews 10, pages 33-47 (2006), which is incorporated herein by reference. Both CSA and OSA can be manifested in periodic breathing patterns.
- U.S. Patent Application Publication US 2004/0230105 Al describes a method for analyzing respiratory signals using a Fuzzy Logic Decision Algorithm (FLDA). The method may be used to associate respiratory disorders with obstructive apnea, hypopnea, central apnea, or other conditions.
- FLDA Fuzzy Logic Decision Algorithm
- U.S. Patent Application Publication US 2002/0002327 Al and U.S. Patent 6,839,581 describe methods for detecting Cheyne-Stokes respiration, which may be used on patients with heart failure.
- the methods involve performing spectral analysis of overnight oximetry recordings, from which a classification tree is generated. Another method, based on monitoring oxygen saturation and calculating the slope of desaturation events, is described in U.S. Patent 6,760,608. Yet another method for classifying sleep apneas is described in U.S. Patent 6,856,829. In this case, pulse waves from the body of a patient are detected, and the envelope of the pulse waves is created by connecting every peak of the pulse waves. The normalized amplitude and period of the envelope are used in determining whether the patient has OSA, CSA, or mixed sleep apnea syndrome. The disclosures of the patents and patent applications cited above are incorporated herein by reference.
- Photoplethysmograph devices known commonly as pulse oximeters, provide instantaneous in vivo measurement of arterial oxygenation by determining the color of blood between a light source and a photodetector. To determine the blood oxygen saturation, light absorption measurement is carried out at two wavelengths in the red and infrared ranges. The difference between background absorption during diastole and peak absorption during systole at both wavelengths is used to compute the blood oxygen saturation.
- Photoplethysmograph signals provide information not only on blood oxygenation, but also on other physiological signs.
- U.S. Patent 5,588,425 describes the use of a pulse oximeter in validating the heart rate and/or R-R intervals of an ECG, and for discriminating between sleep and wakefulness in a monitored subject. It also describes a method for distinguishing between valid pulse waveforms in the oximeter signal.
- U.S. Patent 7,001,337 describes a method for obtaining physiological parameter information related to respiration rate, heart rate, heart rate variability, blood volume variability and/or the autonomic nervous system using photoplethysmography.
- US Patent Application Publication 2007/0213622 describes a method for diagnosis that includes receiving a signal, such as a photoplethysmograph signal, that is associated with blood oxygen saturation of a patient during sleep.
- the signal is filtered and processed to detect a pattern corresponding to multiple cycles of periodic breathing.
- Embodiments of the present invention that are described hereinbelow provide improved methods, systems and software for detection and analysis of periodic breathing patterns.
- the disclosed techniques permit such patterns to be visualized for rapid diagnosis and generate a prognostic indicator of heart disease with high sensitivity and specificity.
- a method for diagnosis including receiving a signal associated with respiration of a patient.
- the signal is processed so as to identify features that are indicative of beginning and end times of apnea episodes.
- Time shifts between recurrences of the features are computed and processed so as to generate an output including a plurality of bands corresponding to different multiples of a cycle length of the apnea episodes.
- the signal is indicative of variations in a blood oxygen saturation in a body of the patient due to the apnea episodes.
- the signal is received from a photoplethysmographic sensor coupled to the body of the patient. Additionally or alternatively, processing the signal includes defining a threshold level, and identifying the features as points at which the blood oxygen saturation crosses the threshold level.
- processing the time shifts includes presenting a plot of the bands on a display, wherein presenting the plot includes displaying the time shifts as a function of time over a monitoring period. Additionally or alternatively, processing the time shifts includes generating a histogram of the time shifts, wherein processing the time shifts includes fitting a parametric function to the histogram so as to extract the cycle length from the histogram.
- the parametric function may include a sum of kernel functions.
- the method may include including diagnosing a medical condition of the patient responsively to the cycle length, wherein the medical condition includes a heart failure of the patient, and wherein diagnosing the medical condition includes assessing a severity of the heart failure based on the cycle length.
- apparatus for diagnosis including a sensor, which is configured to be coupled to a body of a patient and to output a signal associated with associated with respiration of the patient.
- a processor is coupled to process the signal so as to identify features that are indicative of beginning and end times of apnea episodes, to compute time shifts between recurrences of the features, and to process the time shifts so as to generate an output including a plurality of bands corresponding to different multiples of a cycle length of the apnea episodes.
- a computer software product including a computer-readable medium in which program instructions are stored, which instructions, when read by a computer, cause the computer to receive a signal associated with respiration of a patient, to process the signal so as to identify features that are indicative of beginning and end times of apnea episodes, to compute time shifts between recurrences of the features, and to process the time shifts so as to generate an output including a plurality of bands corresponding to different multiples of a cycle length of the apnea episodes.
- Implementation of the method and/or system of embodiments of the invention can involve performing or completing selected tasks manually, automatically, or a combination thereof. Moreover, according to actual instrumentation and equipment of embodiments of the method and/or system of the invention, several selected tasks could be implemented by hardware, by software or by firmware or by a combination thereof using an operating system.
- a data processor such as a computing platform for executing a plurality of instructions.
- the data processor includes a volatile memory for storing instructions and/or data and/or a non- volatile storage, for example, a magnetic hard-disk and/or removable media, for storing instructions and/or data.
- a network connection is provided as well.
- a display and/or a user input device such as a keyboard or mouse are optionally provided as well.
- FIGS. IA and IB are schematic, pictorial illustrations of a system for sleep monitoring and diagnosis, in accordance with an embodiment of the present invention
- FIG. 2 is a schematic plot of a photoplethysmograph signal, illustrating a method of processing such signals in accordance with an embodiment of the present invention
- FIGS. 3, 5 and 7 are plots that schematically show patterns of recurring features in blood oxygen saturation signals as a function of time shift, in accordance with an embodiment of the present invention
- FIGS. 4, 6 and 8 are plots that schematically show histograms of the patterns of FIGS. 3, 5 and 7, respectively, in accordance with an embodiment of the present invention
- FIG. 9 is a receiver operating characteristic (ROC) plot, which schematically shows the sensitivity and specificity of predicting heart failure prognosis in accordance with an embodiment of the present invention.
- FIG. 10 is a Kaplan-Meier plot that schematically shows prognosis of heart failure patients as a function of the severity of symptoms classified by a method in accordance with an embodiment of the present invention.
- FIG. HA exemplifies a raw saturation signal as a function of the time in minutes, as acquired according to various exemplary embodiments of the present invention.
- FIG. HB shows the signal of FIG. HA following a noise reduction preprocessing performed according to some embodiments of the present invention.
- FIG. 12A exemplifies a derivative signal as extracted from a saturation signal following a noise reduction preprocessing, according to various exemplary embodiments of the present invention.
- FIG. 12B exemplifies a saturation signal in which desaturation intervals have been marked based on the derivative signal of FIG. 12 A, according to various exemplary embodiments of the present invention.
- FIG. 12C shows the same signal as FIG. 12B, following an saturation reduction thresholding procedure in which a 3 % saturation reduction threshold is employed, according to some embodiments of the present invention.
- FIG. 12D shows the same derivative signal as FIG. 12B, following an saturation reduction thresholding procedure in which a 4 % saturation reduction threshold is employed, according to some embodiments of the present invention.
- FIG. 13 depicts a high level block diagram of a prototype system, according to some embodiments of the present invention.
- FIG. 14 further details a saturation unit of the prototype system of FIG. 13, according to some embodiments of the present invention.
- FIG. 15A shows example of saturation during Cheyne Stokes breathing, as acquired according to some embodiments of the present invention.
- FIG. 15B illustrates a parametric model fitting of 10 minutes of the Cheyne Stokes of FIG. 15 A, using a Gaussian kernel function, according to some embodiments of the present invention.
- FIGS. 16A-B present a chaotic effect of obstructive sleep apnea, as acquired, analyzed and presented according to some embodiments of the present invention.
- the present invention in some embodiments thereof, relates to physiological monitoring and, more particularly, but not exclusively, to the diagnosis of periodic breathing.
- FIGS. 1 and IB are schematic, pictorial illustrations of a system 20 for sleep monitoring and diagnosis, in accordance with an embodiment of the present invention.
- system 20 is used to monitor a patient 22 in a home, clinic or hospital ward environment, although the principles of the present invention may similarly be applied in dedicated sleep laboratories.
- System 20 receives and analyzes a photoplethysmograph signal from a suitable sensor, such as a pulse oximetry device 24.
- Device 24 provides photoplethysmograph signals indicative of blood flow and of the level of oxygen saturation in the patient's blood, which is in turn dependent on respiration.
- the photoplethysmograph signal is thus considered to be a signal that is associated with blood oxygen saturation and with respiration. Since the photoplethysmograph signal is modulated by both the heart rate and respiratory rate, it may also be used to provide a heart rate and respiratory rate signals.
- the sensor signals from device 24 are collected, digitized and processed by a console 28.
- Pulse oximetry device 24 may have the form of a ring, which fits comfortably over one of the fingers on the hand of the patient (see FIG IB). Other configurations of device 24 are not excluded from the scope of the present invention.
- Device 24 can be connected by a wire to a control unit 25, which may conveniently be fastened around the patient's wrist. Alternatively, the control unit may be fastened elsewhere on the patient's forearm, at any suitable location between the hand and the elbow, or elsewhere on the patient's body.
- the control unit may include a display, to present status information and/or readings of monitored parameters, such as heart rate, blood oxygen saturation and heart failure status.
- a connector 29 on the control unit is configured to connect to a console or docking station.
- connector 29 comprises a receptacle for a cable with a standard plug, such as a USB cable.
- the connector may mate directly with a matching connector on a dedicated docking station.
- system 20 may comprise sensors of other types
- the system may receive an ECG signal, measured by skin electrodes, and a respiration signal measured by a respiration sensor.
- ECG signal measured by skin electrodes
- respiration signal measured by a respiration sensor.
- the techniques of monitoring and analysis that are described herein may be combined with EEG, EOG, leg motion sensors, and other sleep and/or cardiac monitoring modalities that are known in the art.
- console 28 may receive signals by telemetry from implantable cardiac devices, such as pacemakers and ICDs.
- Console 28 may process and analyze the signals from pulse oximetry device 24 locally, using the methods described hereinbelow.
- console 28 is coupled to communicate over a network 30, such as a telephone network or the Internet, with a diagnostic processor 32.
- a network 30 such as a telephone network or the Internet
- Processor 32 typically comprises a general-purpose computer processor (which may be embedded in a bedside or remote monitor) with suitable software for carrying out the functions described herein. This software may be downloaded to processor 32 in electronic form, or it may alternatively be provided on tangible media, such as optical, magnetic or non-volatile electronic memory.
- Processor 32 analyzes the signals conveyed by console 28 in order to analyze the physiological parameters and extract prognostic information regarding patient 22.
- the processor outputs the results of the analysis to an operator 34, such as a physician, via an output device such as a display 33.
- processor 32 can comprise a special computer processor configured for carrying out the functions described herein.
- processor 32 can be a special computer processor which comprises special firmware embodying computer instructions for carrying out the functions described herein.
- system 20 and processor 32 may be configured to collect and process electrical measurements of thoracic and abdominal movement, using skin electrodes to make a plethysmographic measurement of the patient's respiratory effort or a belt to sense changes in the body perimeter.
- air flow measurement based on a pressure cannula, thermistor, or CO 2 sensor, may be used for respiration sensing.
- ECG electrocardiogram
- pulse oximetry device 24 generate signals that are indicative of absorption and/or reflectance of light at two different wavelengths, typically one red and one infrared, as is known in the art.
- Each signal includes an AC component, which corresponds to the pulsatile change in the signal at the patient's heart rate, and a slow-changing DC component. Comparison of the AC components of the two signals gives a blood oxygen saturation signal.
- at least some of the methods described below can use the signals from only a single source/detector subassembly, or signals provided by other types of sensors, as further detailed hereinabove.
- the saturation signal is preprocessed.
- the preprocessing includes low-pass filtration so as to provide a very-low-frequency (VLF) saturation signal. This filtering removes signal components at frequencies that are greater than or equal to the patient's respiratory frequency, such that the remaining signal reflects trends over multiple respiratory cycles. In some embodiments, the filtering is even more pronounced, and eliminates frequency components outside the Cheyne-Stokes cycle frequency, for example, components below 1/180 Hz or above 1/40 Hz.
- the preprocessing includes identification and removal of noisy events and post-removal signal reconstruction, as further exemplified in the Examples section that follows.
- Processor 32 analyzes shape characteristics of the optionally filtered saturation signal in order to detect episodes of Cheyne-Stokes breathing (CSB).
- This condition is characterized by a regular waxing and waning breathing pattern and occurs particularly among patients with heart failure and in patients who have experienced a stroke.
- CSB is present during sleep, and in more severe cases may also be observed during wakefulness.
- Cheyne- Strokes breathing syndrome is characterized by the following criteria: (1) presence of congestive heart failure or cerebral neurological disease; and (2) respiratory monitoring demonstrates: (a) at least three consecutive cycles of a cyclical crescendo and decrescendo change in breathing amplitude, where cycle length is most commonly in the range of 60 seconds, although the length may vary, and (b) one or both of the following: (i) five or more central sleep apneas or hypopneas per hour of sleep, and (ii) the cyclic crescendo and decrescendo change in breathing amplitude has duration of at least 10 consecutive minutes.
- FIG. 2 is a schematic plot of a raw saturation signal 35, illustrating a method of processing such signals in accordance with an embodiment of the present invention.
- the signal shown in the figure gives a measure of blood oxygen saturation over time during sleep of a patient suffering from recurrent apneas.
- processor 32 analyzes signal 35 to find and mark the times of occurrence of signal features that are indicative of the beginning and end of apnea episodes. For this purpose, a processor identifies local maxima and minima in signal 35. In some embodiments, processor identifies the highest local maximum and lowest local minimum within a given sliding window (for example, once every three minutes). Thus, upper and lower lines 36 and 37 represent the positions of the highest local maximum and lowest local minimum of signal 35.
- processor 32 takes the average of the upper and lower lines as a threshold level 39.
- the processor identifies each intersection of level 39 by the saturation curve of signal 35 as a feature time, and records the time as either a descending (beginning of apnea) or ascending (end of apnea) feature type.
- the processor records only features that represent at least a certain minimal change in the saturation level (for example, at least 4% desaturation).
- the record of feature occurrences as a function of time thus has the form of a binary signal, with transitions between the signal levels corresponding to the zero-crossing times.
- mathematical derivatives are employed for identifying features indicative of apnea episodes. This can be done, for example, by extracting the cumulative sum of the first derivative of the signal (e.g., saturation signal), so as to provide a derivative signal.
- the cumulative sum of the first derivative is preferably extracted after the preprocessing.
- the cumulative sum is preferably calculated by summing the values of the derivatives at sequential sampling time points. A change of sign of the cumulative sum indicates the end of an episode.
- a "feature space” is spanned by two or more properties of the derivative signal and optionally the signal itself (preferably after preprocessing).
- the feature space is the working space for the purpose of classifying the features and identifying features indicative of apnea episodes, as further detailed hereinunder.
- Representative examples of properties suitable for spanning the feature space include, without limitation, slope, duration and desaturation level.
- the spanning of feature space is preceded by a procedure in which two or more intervals over the derivative signal are unified (i.e., considered as one interval although being spaced apart) according to a predetermined criterion or set of criteria.
- the unification procedure is executed for unifying intervals characterized by non-positive changes of the derivative signal.
- the criteria for unifying two such intervals are; (i) the distance between two events is less than a predetermined duration
- the overall saturation reduction of each of the two intervals is sufficiently low compared to adjacent desaturation episodes (e.g., less than twice the saturation reduction thereof).
- features indicative of apnea episodes are preferably identified by applying a saturation reduction thresholding procedure.
- a feature is identified as indicative of an apnea episode if the overall saturation reduction over the time intervals associated with the feature is at least a predetermined saturation reduction threshold (for example, at least 3 % or at least 4 % desaturation).
- the identified features are further analyzed according to distances between starts and end of events so as to produce periodic respiratory breathing event, as further detailed hereinunder.
- FIGS. 1 IA-B and 12A-D exemplify selected operations of the above procedure.
- FIG. HA exemplifies a raw saturation signal (as a function of the time in minutes), and FIG. HB shows the same signal following a noise reduction preprocessing.
- the exemplifies signal there is one noisy peak (shown by a black block arrow in FIG. 1 IA) which has been removed. Once the noisy peak is removed, the signal is reconstructed by adding a synthetic insert so to provide a substantially smooth signal.
- the synthetic insert is shown by white block arrow in FIG. 1 IB.
- FIG. 12A exemplifies a derivative signal as extracted from a saturation signal following a noise reduction preprocessing. Intervals of positive derivative are shown as dash lines and intervals of non-positive derivative are shown as solid lines.
- FIG. 12B exemplifies a saturation signal in which desaturation intervals have been marked based on the derivative signal of FIG. 12A.
- the desaturation intervals are marked as solid lines while other intervals are marked as dash lines.
- Several representative desaturation intervals are marked on FIG. 12B by numerals Ia, Ib, 2, 3a, 3b and 4.
- Intervals Ia and Ib satisfy the unification criteria and are therefore treated as a single interval, referred to hereinunder and in FIGS. 12C-D as interval 1.
- intervals 3a and 3b satisfy the unification criteria and are therefore treated as a single interval, referred to hereinunder and in FIGS. 12C-D as interval 3.
- FIG. 12C shows the same derivative signal as FIG.
- FIG. 12B shows the same derivative signal as FIG. 12B, following an saturation reduction thresholding procedure in which a 4 % saturation reduction threshold is employed.
- Time intervals identified as corresponding to apnea episodes are shown as solid lines. All other intervals are shown as dash lines.
- interval 4 as well as the unified intervals 1 and 3 (which are the unification of intervals Ia, Ib and 3a, 3b, respectively) are identified as corresponding to apnea episodes.
- Interval 2 is excluded since its overall desaturation is less than 3 %..
- FIG. 12D shows the same derivative signal as FIG. 12B, following an saturation reduction thresholding procedure in which a 4 % saturation reduction threshold is employed.
- Time intervals identified as corresponding to apnea episodes are shown as solid lines. All other intervals are shown as dash lines.
- interval 1 and 4 are identified as corresponding to apnea episodes.
- Intervals 2 and 3 are excluded since their overall desaturation is less than 4
- FIG. 3 is a schematic plot 38 of the recurrence function of a saturation signal as a function of time shift, in accordance with an embodiment of the present invention.
- the patient in this case was independently diagnosed as suffering from Cheyne-Stokes breathing syndrome.
- the horizontal axis in FIG. 3 corresponds to time (in minutes) from the beginning of a monitoring session, while the vertical axis represents time shift (in seconds).
- processor 32 For each feature (zero-crossing) occurring at a given time on the X-axis, processor 32 searches backward in time for previous occurrences of the same type of feature (ascending or descending). Each point marked in plot 38 indicates a recurrence of the feature of time X at a shift of time Y.
- Plot 38 shows a clear pattern of bands 40, meaning that recurrences of features in the saturation signal occurred with a consistent, periodic cycle length (in this case, approximately 67 sec).
- the inventors have found this band structure to be characteristic of Cheyne-Stokes breathing, with each band corresponding to a different multiple of the cycle length.
- This sort of plot may be presented by system 20 on display 33 and enables operator 34 to visually diagnose the condition of patient 22.
- the period and strength of the bands appearing on the display give a good indication of the severity of the patient's condition, which is immediately apparent to the operator.
- FIG. 4 is a plot that schematically shows a histogram 44 of the recurrence function of FIG. 3, in accordance with an embodiment of the present invention.
- the histogram compiles the number of recurrence points in the recording of FIG. 3 as a function of the time shift, and can be seen to comprise multiple bands corresponding to multiples of the basic cycle length.
- the histogram may likewise be presented on display 33 in order to give the operator another diagnostic indicator.
- processor 32 may fit a parametric model 46 to histogram 44 in order to automatically extract the period and amplitude of the histogram.
- histogram 44 is fitted to an analytical function CS( ⁇ f ) representing the probability of finding a pair of features ⁇ f seconds apart.
- K 1 (/ 1, 2, ..., ⁇ ).
- CS( ⁇ f ) is calculated a sum, e.g., using the following equation where w, is the weight of the zth kernel function.
- the number n of kernel functions in the fit can be predetermined or it can be a free parameter which is selected to optimize the goodness of the fit.
- at least one, more preferably all the kernel functions is a localized function.
- localized function refers to any function having a local support and which is significantly suppressed far ⁇ e.g., at a distance of about 10 widths of the local support) from the local support.
- Representative examples of localized functions include, without limitation, a Gaussian function, a Lorentzian function, a hyperbolic secant function (also known as sech), a logistic distribution and the like.
- the localized function can be represented as a series or an integral of other functions.
- the localized function can be a Fourier transform, a wavelet transform and the like.
- the kernel functions are Gaussians
- the following expression can be used for the analytical function CS( ⁇ f ):
- ⁇ , ⁇ ( ⁇ ,) where, a is an amplitude factor, ⁇ is the average distance between consecutive apneas; ⁇ is the standard deviation of the distance between consecutive apneas, and the summation is taken over multiples / of the average distance ⁇ .
- the parameters a, ⁇ , ⁇ and optionally n are preferably selected to optimally fit the histogram of distances between features.
- model 46 in this case is strongly periodic, with a cycle length of about 67 sec, and with a high amplitude and low standard deviation (substantially less than the period of the pattern). These features thus give a rapid quantitative assessment of the patient's respiratory conditions.
- processor 32 evaluates the slope of the saturation signal (or of the DC component of the pulse oximeter signal) for each desaturation episode. This is particularly useful for ensuring that the sequences of cyclic breathing episodes are indeed associated with the severity of heart failure status. In central apnea, or when the heart failure state is grave, the slope of the exit from the cycle is moderate, e.g., similar to the typical (or specific) entry slope.
- processor 32 requires that the sequence comprise mainly (typically at least 80 %) events of moderate slope.
- PCT Patent Application PCT/IL2006/000148 the contents of which are hereby incorporated by reference, defines formal criteria for assessing the symmetry of periodic breathing episodes, which may also be used in the present context for distinguishing Cheyne-Stokes events.).
- the requirement of moderate slope may also be applied to the median slope value.
- the observations with respect to the symmetry of the periodic breathing patterns apply both to the slowly-varying heart rate and saturation signals and to the envelopes of the other, rapidly- varying signals shown by the other traces.
- envelope in this context typically means a signal derived from the local minima and/or local maxima of another signal, with or without smoothing (by convolution or resampling, for example). "Envelopes” may also be derived by other mathematical operations known in the art, such as application of Hubert transforms.
- the inventors have found that periodic breathing patterns associated with CSA generally tend to be more symmetrical than the patterns associated with OSA, presumably due to the different physiological mechanisms that are involved in the different types of apneas.
- processor 32 may validate the prognostic value of the Cheyne-Stokes marker by considering only events with mild exit slope from desaturation events.
- the inventors found that computing the slope of the saturation curve by fitting a line (by the least-square method) to the curve over a nine-second epoch, and requiring that the slope of the line be less then 0.7 percent/second is a good implementation of this mild desaturation condition.
- processor 32 typically detects signal components that have a period greater than a minimum period of at least 30 sec. For example, a periodic breathing pattern is classified as a Cheyne-Stokes breathing if the median cycle length is above 55 seconds and the median desaturation value is at least 2 %. or at least 3 % or at least 4 %.
- time segments with steep exit saturation slope typically correspond to obstructive apnea/hypopnea events.
- Other features of obstructive apnea/hypopnea time segments include short wavelength, large vasomotion, and large heart rate modulations. These phenomena are generally associated with good prognosis, since they reflect the patient's ability to manifest enhanced sympathetic activity.
- processor 32 may also process an AC absorption or reflectance signal that is output by device 24 in order to compute a heart rate, as is known in the art.
- the AC signal may also be analyzed to detect a beat morphology.
- the processor can identify certain aberrations in this morphology as arrhythmias, such as premature ventricular contractions (PVCs).
- PVCs premature ventricular contractions
- the processor optionally keeps a record of the occurrences of such arrhythmias, in a manner similar to a Holter monitor, but without requiring the use of ECG leads.
- the total number of abnormal heart beats and (specifically PVCs) that are accumulated in such a record, particularly during sleep is indicative of bad prognosis.
- the processor may be configured to count the number of premature beats only during sleep or during episodes of Cheyne-Stokes breathing.
- processor 32 may use the time characteristics of the patient's Cheyne-Stokes episodes as a prognostic indicator.
- FIGS. 5 and 6 are schematic plots of the recurrence function and histogram, respectively, of a saturation signal in another patient, in accordance with an embodiment of the present invention.
- the severity of the patient's condition is reflected in a highly-periodic histogram 48 of the recurrence function.
- a parametric curve 50, fitted to histogram 48 using the equation shown above, indicates that the Cheyne-Stokes cycle length in this case is about 82 sec.
- FIG. 7 and 8 are schematic plots of the recurrence function and histogram, respectively, of a saturation signal in still another patient, in accordance with an embodiment of the present invention.
- a histogram 54 in FIG. 8 does not exhibit any meaningful periodicity, as shown by a parametric curve 56 that is fit to the histogram.
- motion artifacts are characterized by local maxima well above normal beat range (for example, at least twice the normal value).
- the prevalence of motion artifacts can be used in detecting movement, which indicate whether the patient is in a sleep or waking state.
- a motion sensor may be used to detect arousals.
- Processor 32 may additionally extract other cardiorespiratory parameters from the signal, either directly or indirectly.
- the processor may apply very-low- frequency filtering to the heart rate in order to detect heart rate modulations.
- the envelope of the signal may be processed in order to detect characteristics of vasomodulation, i.e., arterial dilation and constriction.
- processor 32 computes a respiration energy and/or rate characteristic based on high-frequency components of the signal. Respiratory sinus arrhythmia is a natural cycle of arrhythmia that occurs in healthy people through the influence of breathing on the flow of sympathetic and vagus impulses to the sinoatrial node in the heart. This effect may be used to calculate respiration from heart rate.
- Very-low-frequency components of the characteristic can be indicative of a respiration modulation.
- Processor 32 can combine the various cardiac, respiratory and vasomodulation parameters described above in order to provide a general picture of cardiorespiratory effects, all on the basis of the photoplethysmograph signals. Similar procedures to those described above can be applied to the detrended AC photoplethysmograph signal.
- One way to perform detrending is to replace the photoplethysmograph signal with its amplitude feature (maximum minus minimum signal). Other methods include subtracting a polynomial that approximates the signal, or using local maxima or local minima features.
- the processor applies very-low-frequency filtering followed by outlier rejection, and then computes the median vasomotion of each sequence.
- the processor may perform similar analyses on heart rate and respiratory signals from other sources. Arousals can estimated from motion artifacts as described above or from other data if available (such as EEG alpha and beta frequencies, or scorer marking, or a motion sensor).
- Information regarding sleep/wake state can be combined with the Cheyne- Stokes time to determine specific, cumulative Cheyne-Stokes time during sleep.
- the total Cheyne-Stokes time and percentage of Cheyne-Stokes time during sleep have prognostic value: a large percentage of Cheyne-Stokes time is associated with mortality and high levels of brain natriuretic peptide (BNP), which are associated with severity of heart failure.
- BNP brain natriuretic peptide
- information about sleep time can be used to ensure that low Cheyne-Stokes duration is not associated with little or no sleep.
- the information regarding the Cheyne-Stokes time can also be combined with the general picture of cardiorespiratory effects in order to provide some or all of the following combined information for each Cheyne-Stokes sequence during sleep: duration, median wavelength, median desaturation, median vasomotion, median heart rate modulation, median respiratory modulation, number of PVCs and other premature beats, and arousal index (e.g., number of arousals).
- arousal index e.g., number of arousals.
- Each of the above parameters can also be computed separately for REM sleep and NREM sleep.
- Cheyne-Stokes breathing and attendant heart failure prognosis provide the physician with a clear, immediate, visual indication of the patient's respiratory condition. They may be used conveniently in performing frequent checks on patient status, both at home and in the hospital. Additionally or alternatively, occasional checks of this sort may be used for risk stratification and screening. As explained above, these methods may be implemented using measurements made solely by pulse oximetry device 24, or alternatively in conjunction with other sensors, as in a multi-monitor polysomnography system, or in an implantable device, or using other types of sensors.
- the inventors in the present patent application performed a similar clinical study of the efficacy of Cheyne-Stokes cycle length as a prognostic indicator for heart failure.
- the cycle length (CL) was measured, using the techniques described above and illustrated in FIGS. 3-8, for a group of 109 heart failure patients.
- the median CL for this patient group was found to be 51 sec.
- High CL, above the median, was taken as a trial prognostic indicator for the patient group, for comparison with BNP level.
- the clinical progress of the patients' heart failure was monitored for a six-month period following the CL and BNP measurements in order to compare the prognostic value of these two indicators.
- FIG. 9 is a receiver operating characteristic (ROC) plot, which schematically compares the sensitivity and specificity of BNP and of CL of Cheyne-Stokes breathing in predicting heart failure prognosis, in accordance with an embodiment of the present invention.
- An upper trace 62 is the ROC curve for Cheyne-Stokes CL>51, while a lower trace 60 is the ROC curve for the BNP marker.
- both CL and BNP were tested against hospitalization and mortality of the patients over the six-month period of the study. The plot shows that the CL marker gave greater sensitivity and specificity in predicting which patients would be hospitalized or would die during the study period.
- FIG. 10 is a Kaplan-Meier plot of a six-month survival function of the heart failure patients as a function of Cheyne Stokes CL, in accordance with an embodiment of the present invention.
- patients were classified into two groups: one group with CL>51 , and the other with CL ⁇ 51.
- the "survival" function corresponds to the number of patients who did not die and were not hospitalized over the study period.
- An upper trace 68 in the figure shows the survival rate for the group with CL ⁇ 51, while a lower trace 66 shows the much lower survival rate for patients with CL>51.
- the plot demonstrates the strength of CL as a prognostic marker.
- FIGS. 9 and 10 show that CL measurement based on photoplethysmographic monitoring during sleep may be used effectively for the prognosis of heart failure patients.
- this sort of monitoring is simple to carry out in the patient's home or hospital bed and may be performed at regular intervals, at low cost and minimal discomfort to the patient. It provides physicians with an accurate prognostic indicator, which they can use in choosing the optimal treatment, such as determining whether a patient requires hospitalization, and adjusting treatment parameters (such as drug titration) based on changes in the patient's condition.
- the physician may measure and quantify the patient's symptoms prior to initiating or making a change in treatment, and may repeat the measurement thereafter in order to assess the effectiveness of the treatment and possibly readjust treatment parameters.
- the physician may fix a specific critical Cheyne- Stokes CL for individual patients, and then set a monitoring system to alarm whenever this CL is exceeded.
- FIG. 13 depicts a high level block diagram of the prototype system.
- the block diagram shows sleep analysis from at least one of the following signals: saturation signal, pulse rate, PPG and respiration flow.
- the system comprises several analysis units.
- a saturation unit which is responsible of desaturation event detection, Cheyne stokes respiration pattern classification and periodic respiration breathing (PRB).
- a Plethysmograph unit which extracts location and magnitude of the PPG. Both are used in order to extract AFIB rhythms, respiratory rate and sleep wake features.
- a pulse rate unit which calculates pulse rate slope calculation and pulse rate noise extraction for the determination of sleep wake epochs.
- a sleep wake classification unit is utilized according to the input data; each feature is associated with probability for sleep and probability for wake and a Viterbi algorithm is performed for sleep wake hypnogram extraction.
- a respiratory classification unit receives hypnogram and desaturation events and classifies highly periodic desaturation events as central sleep apnea and also filter noisy wake desaturation events in order to produce respiratory events.
- the saturation unit is further detailed in FIG. 14.
- the saturation unit can include several sub-units which operate as described above with reference to FIGS. 1 IA-B and
- the preprocessing subunit performs the preprocessing operation, as further detailed hereinabove
- the CumSum subunit calculates and provides the derivative signal as further detailed hereinabove
- the Desat Features subunit performs the saturation reduction thresholding procedure as further detailed hereinabove
- the unification event subunit unifies intervals over the derivative signal as further detailed hereinabove
- the classification subunit outputs the desaturation features according to their classification.
- CSB Cheyne Stokes breathing
- FIG. 15A shows example of saturation during Cheyne Stokes breathing
- FIG. 15B illustrates a parametric model fitting of 10 minutes of the Cheyne Stokes using a Gaussian kernel function.
- the cycle length is of about 58 seconds.
- FIGS. 16A-B present the chaotic effect of obstructive sleep apnea. These features thus give a rapid quantitative assessment of the patient's respiratory conditions.
- a set of rules are utilized to determine whether a set of apneas are associated with CSB.
- the rules can be based on the number of periodic desaturation, the width of the standard deviation and the perturbation needed in order to fit the parametric model to the data. Two levels of CSB classification are initiated in case that suspected periodic of
- CSB 3 % or 4 % detected CSB.
- a first level a set of four highly periodic desaturation events with cycle length in the zone of the average distance between consecutive apneas, are classified as CSB.
- a second level a set of seven periodic desaturation events are classified as CSB.
- the operation of saturation processing is finished once desaturation events, periodic respiratory breathing and Cheyne stokes breathing are extracted and ready to be used in sleep wake classification unit.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Physiology (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
A method for diagnosis comprises receiving a signal associated with respiration of a patient. The signal is processed so as to identify features that are indicative of beginning and end times of apnea episodes. Time shifts between recurrences of the features are computed and processed so as to generate an output comprising a plurality of bands corresponding to different multiples of a cycle length of the apnea episodes.
Description
DIAGNOSIS OF PERIODIC BREATHING
RELATED APPLICATION/S
This application claims the benefit of U.S. Patent Application No. 61/072,327, filed March 27, 2008, the contents of which are hereby incorporated by reference as if fully set forth herein.
FIELD AND BACKGROUND OF THE INVENTION
The present invention, in some embodiments thereof, relates to physiological monitoring and, more particularly, but not exclusively, to the diagnosis of periodic breathing.
Sleep apneas commonly occur in conjunction with a variety of cardiorespiratory disorders. The relationship between sleep apnea and heart failure, for example, is surveyed by Bradley et al. in two articles entitled "Sleep Apnea and Heart Failure," including "Part I: Obstructive Sleep Apnea," Circulation 107, pages 1671-1678 (2003), and "Part II: Central Sleep Apnea," Circulation 107, pages 1822-1826 (2003), which are incorporated herein by reference. The authors define "apnea" as a cessation of airflow for more than 10 sec. This term is distinguished from "hypopnea," which is a reduction in but not complete cessation of airflow to less than 50% of normal, usually in association with a reduction in oxyhemoglobin saturation (commonly referred to as "desaturation").
Sleep apneas and hypopneas are generally believed to fall into two categories: obstructive, due to collapse of the pharynx; and central, due to withdrawal of central respiratory drive to the muscles of respiration. Central sleep apnea (CSA) is commonly associated with Cheyne-Stokes respiration, which is a form of periodic breathing in which central apneas and hypopneas alternate with periods of hyperventilation, with a waxing-waning pattern of tidal volume. CSA is believed to arise as the result of heart failure, though obstructive sleep apnea (OSA) may also occur in heart failure patients.
Both OSA and CSA increase the strain on the cardiovascular system and thus worsen the prognosis of the heart failure patient. In some cases, both types of apneas may occur in the same patient, even at the same time (superposition). Classifying respiratory events as central or obstructive is considered to be a critical point, since
treatment may differ according to the type of events, as pointed out by Pepin et al. in "Cheyne-Stokes Respiration with Central Sleep Apnea in Chronic Heart Failure: Proposals for a Diagnostic and Therapeutic Strategy," Sleep Medicine Reviews 10, pages 33-47 (2006), which is incorporated herein by reference. Both CSA and OSA can be manifested in periodic breathing patterns.
Various methods have been proposed in the patent literature for automated apnea detection and diagnosis based on patient monitoring during sleep. For example, U.S. Patent Application Publication US 2004/0230105 Al describes a method for analyzing respiratory signals using a Fuzzy Logic Decision Algorithm (FLDA). The method may be used to associate respiratory disorders with obstructive apnea, hypopnea, central apnea, or other conditions. As another example, U.S. Patent Application Publication US 2002/0002327 Al and U.S. Patent 6,839,581 describe methods for detecting Cheyne-Stokes respiration, which may be used on patients with heart failure. The methods involve performing spectral analysis of overnight oximetry recordings, from which a classification tree is generated. Another method, based on monitoring oxygen saturation and calculating the slope of desaturation events, is described in U.S. Patent 6,760,608. Yet another method for classifying sleep apneas is described in U.S. Patent 6,856,829. In this case, pulse waves from the body of a patient are detected, and the envelope of the pulse waves is created by connecting every peak of the pulse waves. The normalized amplitude and period of the envelope are used in determining whether the patient has OSA, CSA, or mixed sleep apnea syndrome. The disclosures of the patents and patent applications cited above are incorporated herein by reference.
It has been suggested that sleep monitoring can be used for assessing cardiorespiratory risk. For example, U.S. Patent 5,902,250, whose disclosure is incorporated herein by reference, describes a home-based, wearable, self-contained system that determines sleep-state and respiratory pattern, and assesses cardiorespiratory risk. Cardiac disorders (such as cardiac arrhythmia or myocardial ischemia) that are known to be linked to certain respiratory disorders also may be inferred upon detection of such respiratory disorders.
Photoplethysmograph devices, known commonly as pulse oximeters, provide instantaneous in vivo measurement of arterial oxygenation by determining the color of
blood between a light source and a photodetector. To determine the blood oxygen saturation, light absorption measurement is carried out at two wavelengths in the red and infrared ranges. The difference between background absorption during diastole and peak absorption during systole at both wavelengths is used to compute the blood oxygen saturation.
Photoplethysmograph signals provide information not only on blood oxygenation, but also on other physiological signs. For example, U.S. Patent 5,588,425 describes the use of a pulse oximeter in validating the heart rate and/or R-R intervals of an ECG, and for discriminating between sleep and wakefulness in a monitored subject. It also describes a method for distinguishing between valid pulse waveforms in the oximeter signal. U.S. Patent 7,001,337 describes a method for obtaining physiological parameter information related to respiration rate, heart rate, heart rate variability, blood volume variability and/or the autonomic nervous system using photoplethysmography. US Patent Application Publication 2007/0213622 describes a method for diagnosis that includes receiving a signal, such as a photoplethysmograph signal, that is associated with blood oxygen saturation of a patient during sleep. The signal is filtered and processed to detect a pattern corresponding to multiple cycles of periodic breathing. The disclosures of the above-mentioned patents and patent applications are incorporated herein by reference.
SUMMARY OF THE INVENTION
Embodiments of the present invention that are described hereinbelow provide improved methods, systems and software for detection and analysis of periodic breathing patterns. The disclosed techniques permit such patterns to be visualized for rapid diagnosis and generate a prognostic indicator of heart disease with high sensitivity and specificity.
There is therefore provided, in accordance with an embodiment of the present invention, a method for diagnosis, including receiving a signal associated with respiration of a patient. The signal is processed so as to identify features that are indicative of beginning and end times of apnea episodes. Time shifts between recurrences of the features are computed and processed so as to generate an output
including a plurality of bands corresponding to different multiples of a cycle length of the apnea episodes.
In some embodiments, the signal is indicative of variations in a blood oxygen saturation in a body of the patient due to the apnea episodes. In one embodiment, the signal is received from a photoplethysmographic sensor coupled to the body of the patient. Additionally or alternatively, processing the signal includes defining a threshold level, and identifying the features as points at which the blood oxygen saturation crosses the threshold level.
In a disclosed embodiment, processing the time shifts includes presenting a plot of the bands on a display, wherein presenting the plot includes displaying the time shifts as a function of time over a monitoring period. Additionally or alternatively, processing the time shifts includes generating a histogram of the time shifts, wherein processing the time shifts includes fitting a parametric function to the histogram so as to extract the cycle length from the histogram. The parametric function may include a sum of kernel functions.
The method may include including diagnosing a medical condition of the patient responsively to the cycle length, wherein the medical condition includes a heart failure of the patient, and wherein diagnosing the medical condition includes assessing a severity of the heart failure based on the cycle length. There is also provided, in accordance with an embodiment of the present invention, apparatus for diagnosis, including a sensor, which is configured to be coupled to a body of a patient and to output a signal associated with associated with respiration of the patient. A processor is coupled to process the signal so as to identify features that are indicative of beginning and end times of apnea episodes, to compute time shifts between recurrences of the features, and to process the time shifts so as to generate an output including a plurality of bands corresponding to different multiples of a cycle length of the apnea episodes.
There is additionally provided, in accordance with an embodiment of the present invention, a computer software product, including a computer-readable medium in which program instructions are stored, which instructions, when read by a computer, cause the computer to receive a signal associated with respiration of a patient, to process the signal so as to identify features that are indicative of beginning and end times of
apnea episodes, to compute time shifts between recurrences of the features, and to process the time shifts so as to generate an output including a plurality of bands corresponding to different multiples of a cycle length of the apnea episodes.
Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.
Implementation of the method and/or system of embodiments of the invention can involve performing or completing selected tasks manually, automatically, or a combination thereof. Moreover, according to actual instrumentation and equipment of embodiments of the method and/or system of the invention, several selected tasks could be implemented by hardware, by software or by firmware or by a combination thereof using an operating system.
For example, hardware for performing selected tasks according to embodiments of the invention could be implemented as a chip or a circuit. As software, selected tasks according to embodiments of the invention could be implemented as a plurality of software instructions being executed by a computer using any suitable operating system. In an exemplary embodiment of the invention, one or more tasks according to exemplary embodiments of method and/or system as described herein are performed by a data processor, such as a computing platform for executing a plurality of instructions. Optionally, the data processor includes a volatile memory for storing instructions and/or data and/or a non- volatile storage, for example, a magnetic hard-disk and/or removable media, for storing instructions and/or data. Optionally, a network connection is provided as well. A display and/or a user input device such as a keyboard or mouse are optionally provided as well.
BRIEF DESCRIPTION OF THE DRAWINGS
Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the
drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced. FIGS. IA and IB are schematic, pictorial illustrations of a system for sleep monitoring and diagnosis, in accordance with an embodiment of the present invention;
FIG. 2 is a schematic plot of a photoplethysmograph signal, illustrating a method of processing such signals in accordance with an embodiment of the present invention; FIGS. 3, 5 and 7 are plots that schematically show patterns of recurring features in blood oxygen saturation signals as a function of time shift, in accordance with an embodiment of the present invention;
FIGS. 4, 6 and 8 are plots that schematically show histograms of the patterns of FIGS. 3, 5 and 7, respectively, in accordance with an embodiment of the present invention;
FIG. 9 is a receiver operating characteristic (ROC) plot, which schematically shows the sensitivity and specificity of predicting heart failure prognosis in accordance with an embodiment of the present invention; and
FIG. 10 is a Kaplan-Meier plot that schematically shows prognosis of heart failure patients as a function of the severity of symptoms classified by a method in accordance with an embodiment of the present invention.
FIG. HA exemplifies a raw saturation signal as a function of the time in minutes, as acquired according to various exemplary embodiments of the present invention. FIG. HB shows the signal of FIG. HA following a noise reduction preprocessing performed according to some embodiments of the present invention.
FIG. 12A exemplifies a derivative signal as extracted from a saturation signal following a noise reduction preprocessing, according to various exemplary embodiments of the present invention. FIG. 12B exemplifies a saturation signal in which desaturation intervals have been marked based on the derivative signal of FIG. 12 A, according to various exemplary embodiments of the present invention.
FIG. 12C shows the same signal as FIG. 12B, following an saturation reduction thresholding procedure in which a 3 % saturation reduction threshold is employed, according to some embodiments of the present invention.
FIG. 12D shows the same derivative signal as FIG. 12B, following an saturation reduction thresholding procedure in which a 4 % saturation reduction threshold is employed, according to some embodiments of the present invention.
FIG. 13 depicts a high level block diagram of a prototype system, according to some embodiments of the present invention.
FIG. 14 further details a saturation unit of the prototype system of FIG. 13, according to some embodiments of the present invention.
FIG. 15A shows example of saturation during Cheyne Stokes breathing, as acquired according to some embodiments of the present invention.
FIG. 15B illustrates a parametric model fitting of 10 minutes of the Cheyne Stokes of FIG. 15 A, using a Gaussian kernel function, according to some embodiments of the present invention.
FIGS. 16A-B present a chaotic effect of obstructive sleep apnea, as acquired, analyzed and presented according to some embodiments of the present invention.
DESCRIPTION OF SPECIFIC EMBODIMENTS OF THE INVENTION The present invention, in some embodiments thereof, relates to physiological monitoring and, more particularly, but not exclusively, to the diagnosis of periodic breathing.
Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details of construction and the arrangement of the components and/or methods set forth in the following description and/or illustrated in the drawings and/or the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.
System Overview FIGS. 1 and IB are schematic, pictorial illustrations of a system 20 for sleep monitoring and diagnosis, in accordance with an embodiment of the present invention.
In this embodiment, system 20 is used to monitor a patient 22 in a home, clinic or
hospital ward environment, although the principles of the present invention may similarly be applied in dedicated sleep laboratories.
System 20 receives and analyzes a photoplethysmograph signal from a suitable sensor, such as a pulse oximetry device 24. Device 24 provides photoplethysmograph signals indicative of blood flow and of the level of oxygen saturation in the patient's blood, which is in turn dependent on respiration. In the context of the present patent application and in the claims, the photoplethysmograph signal is thus considered to be a signal that is associated with blood oxygen saturation and with respiration. Since the photoplethysmograph signal is modulated by both the heart rate and respiratory rate, it may also be used to provide a heart rate and respiratory rate signals. The sensor signals from device 24 are collected, digitized and processed by a console 28.
Pulse oximetry device 24 may have the form of a ring, which fits comfortably over one of the fingers on the hand of the patient (see FIG IB). Other configurations of device 24 are not excluded from the scope of the present invention. Device 24 can be connected by a wire to a control unit 25, which may conveniently be fastened around the patient's wrist. Alternatively, the control unit may be fastened elsewhere on the patient's forearm, at any suitable location between the hand and the elbow, or elsewhere on the patient's body. The control unit may include a display, to present status information and/or readings of monitored parameters, such as heart rate, blood oxygen saturation and heart failure status. A connector 29 on the control unit is configured to connect to a console or docking station. In the illustrated embodiment, connector 29 comprises a receptacle for a cable with a standard plug, such as a USB cable. Alternatively, the connector may mate directly with a matching connector on a dedicated docking station. Additionally or alternatively, system 20 may comprise sensors of other types
(not shown), for collecting other physiological signals. For example, the system may receive an ECG signal, measured by skin electrodes, and a respiration signal measured by a respiration sensor. Additionally or alternatively, the techniques of monitoring and analysis that are described herein may be combined with EEG, EOG, leg motion sensors, and other sleep and/or cardiac monitoring modalities that are known in the art.
As another example, console 28 may receive signals by telemetry from implantable cardiac devices, such as pacemakers and ICDs.
Console 28 may process and analyze the signals from pulse oximetry device 24 locally, using the methods described hereinbelow. In the present embodiment, however, console 28 is coupled to communicate over a network 30, such as a telephone network or the Internet, with a diagnostic processor 32. This configuration permits sleep studies to be performed simultaneously in multiple different locations. Processor 32 typically comprises a general-purpose computer processor (which may be embedded in a bedside or remote monitor) with suitable software for carrying out the functions described herein. This software may be downloaded to processor 32 in electronic form, or it may alternatively be provided on tangible media, such as optical, magnetic or non-volatile electronic memory. Processor 32 analyzes the signals conveyed by console 28 in order to analyze the physiological parameters and extract prognostic information regarding patient 22. The processor outputs the results of the analysis to an operator 34, such as a physician, via an output device such as a display 33. Alternatively, processor 32 can comprise a special computer processor configured for carrying out the functions described herein. For example, processor 32 can be a special computer processor which comprises special firmware embodying computer instructions for carrying out the functions described herein.
While the embodiments herein are described with a particular emphasis to methods and apparatus for monitoring and diagnosis during sleep, it is to be understood that more detailed reference to diagnosis during sleep is not to be interpreted as limiting the scope of the invention in any way. The principles of the present invention may also be applied, mutatis mutandis, to patients who are awake. For example, these methods and apparatus may be used in monitoring patients who are reclining or otherwise at rest, even if they are not asleep. The configuration of system 20 that is shown in FIG. 1 is described here by way of example, and the principles of the present invention may likewise be applied in other patient monitoring configurations. Some applicable configurations are shown, for example, in the above-mentioned US 2007/0213622. Furthermore, although the inventors have found it convenient to collect and process photoplethysmograph signals as the basis for diagnosis of periodic breathing patterns, the principles of the present invention may similarly be applied to other types of physiological signals that are indicative of patient respiration.
For example, system 20 and processor 32 may be configured to collect and process electrical measurements of thoracic and abdominal movement, using skin electrodes to make a plethysmographic measurement of the patient's respiratory effort or a belt to sense changes in the body perimeter. Additionally or alternatively, air flow measurement, based on a pressure cannula, thermistor, or CO2 sensor, may be used for respiration sensing. In other embodiments of the present invention, other sensors that are known in the art of polysomnography, such as a capnograph, may be used in detecting sleep apneas, either in conjunction with or separately from the pulse oximeter used in the techniques described above. In yet another embodiment, an electrocardiogram (ECG) signal may be used in detecting apneas, since the ECG signal also exhibits changes that are associated with respiration.
Signal Processing and Display
In the description that follows, techniques for processing respiration-related signals and displaying processing results are described, for convenience and clarity of explanation, with reference to system 20, as shown in FIGS. IA and IB. These techniques, however, are in no way limited to this particular system, and they may likewise be applied in substantially any suitable system configuration for collection and processing of respiration-related signals.
In various exemplary embodiments of the invention pulse oximetry device 24 generate signals that are indicative of absorption and/or reflectance of light at two different wavelengths, typically one red and one infrared, as is known in the art. Each signal includes an AC component, which corresponds to the pulsatile change in the signal at the patient's heart rate, and a slow-changing DC component. Comparison of the AC components of the two signals gives a blood oxygen saturation signal. Alternatively, at least some of the methods described below can use the signals from only a single source/detector subassembly, or signals provided by other types of sensors, as further detailed hereinabove.
In some embodiments of the present invention the saturation signal is preprocessed. In some embodiments, the preprocessing includes low-pass filtration so as to provide a very-low-frequency (VLF) saturation signal. This filtering removes signal components at frequencies that are greater than or equal to the patient's respiratory frequency, such that the remaining signal reflects trends over multiple
respiratory cycles. In some embodiments, the filtering is even more pronounced, and eliminates frequency components outside the Cheyne-Stokes cycle frequency, for example, components below 1/180 Hz or above 1/40 Hz. In some embodiments of the present invention the preprocessing includes identification and removal of noisy events and post-removal signal reconstruction, as further exemplified in the Examples section that follows.
Processor 32 analyzes shape characteristics of the optionally filtered saturation signal in order to detect episodes of Cheyne-Stokes breathing (CSB). This condition is characterized by a regular waxing and waning breathing pattern and occurs particularly among patients with heart failure and in patients who have experienced a stroke. CSB is present during sleep, and in more severe cases may also be observed during wakefulness. According to the American Academy of Sleep Medicine, Cheyne- Strokes breathing syndrome (CSBS) is characterized by the following criteria: (1) presence of congestive heart failure or cerebral neurological disease; and (2) respiratory monitoring demonstrates: (a) at least three consecutive cycles of a cyclical crescendo and decrescendo change in breathing amplitude, where cycle length is most commonly in the range of 60 seconds, although the length may vary, and (b) one or both of the following: (i) five or more central sleep apneas or hypopneas per hour of sleep, and (ii) the cyclic crescendo and decrescendo change in breathing amplitude has duration of at least 10 consecutive minutes.
FIG. 2 is a schematic plot of a raw saturation signal 35, illustrating a method of processing such signals in accordance with an embodiment of the present invention. The signal shown in the figure gives a measure of blood oxygen saturation over time during sleep of a patient suffering from recurrent apneas. In some embodiments of the present invention processor 32 analyzes signal 35 to find and mark the times of occurrence of signal features that are indicative of the beginning and end of apnea episodes. For this purpose, a processor identifies local maxima and minima in signal 35. In some embodiments, processor identifies the highest local maximum and lowest local minimum within a given sliding window (for example, once every three minutes). Thus, upper and lower lines 36 and 37 represent the positions of the highest local maximum and lowest local minimum of signal 35.
In some embodiments of the present invention processor 32 takes the average of the upper and lower lines as a threshold level 39. In these embodiments, the processor identifies each intersection of level 39 by the saturation curve of signal 35 as a feature time, and records the time as either a descending (beginning of apnea) or ascending (end of apnea) feature type. To ensure that the features represent actual apneas, the processor records only features that represent at least a certain minimal change in the saturation level (for example, at least 4% desaturation). The record of feature occurrences as a function of time thus has the form of a binary signal, with transitions between the signal levels corresponding to the zero-crossing times. In some embodiments of the present invention mathematical derivatives are employed for identifying features indicative of apnea episodes. This can be done, for example, by extracting the cumulative sum of the first derivative of the signal (e.g., saturation signal), so as to provide a derivative signal. In embodiments in which preprocessing is employed, the cumulative sum of the first derivative is preferably extracted after the preprocessing. The cumulative sum is preferably calculated by summing the values of the derivatives at sequential sampling time points. A change of sign of the cumulative sum indicates the end of an episode.
Once the derivative signal is provided, a "feature space" is spanned by two or more properties of the derivative signal and optionally the signal itself (preferably after preprocessing). The feature space is the working space for the purpose of classifying the features and identifying features indicative of apnea episodes, as further detailed hereinunder. Representative examples of properties suitable for spanning the feature space include, without limitation, slope, duration and desaturation level.
In some embodiments of the present invention, the spanning of feature space is preceded by a procedure in which two or more intervals over the derivative signal are unified (i.e., considered as one interval although being spaced apart) according to a predetermined criterion or set of criteria. Preferably, the unification procedure is executed for unifying intervals characterized by non-positive changes of the derivative signal. In some embodiments of the present invention, the criteria for unifying two such intervals are; (i) the distance between two events is less than a predetermined duration
(say, 20 seconds), and (ii) the overall saturation reduction of each of the two intervals is
sufficiently low compared to adjacent desaturation episodes (e.g., less than twice the saturation reduction thereof).
Once the feature space is spanned, features indicative of apnea episodes are preferably identified by applying a saturation reduction thresholding procedure. In various exemplary embodiments of the invention a feature is identified as indicative of an apnea episode if the overall saturation reduction over the time intervals associated with the feature is at least a predetermined saturation reduction threshold (for example, at least 3 % or at least 4 % desaturation).
The identified features are further analyzed according to distances between starts and end of events so as to produce periodic respiratory breathing event, as further detailed hereinunder.
FIGS. 1 IA-B and 12A-D exemplify selected operations of the above procedure. FIG. HA exemplifies a raw saturation signal (as a function of the time in minutes), and FIG. HB shows the same signal following a noise reduction preprocessing. In the exemplifies signal, there is one noisy peak (shown by a black block arrow in FIG. 1 IA) which has been removed. Once the noisy peak is removed, the signal is reconstructed by adding a synthetic insert so to provide a substantially smooth signal. The synthetic insert is shown by white block arrow in FIG. 1 IB.
FIG. 12A exemplifies a derivative signal as extracted from a saturation signal following a noise reduction preprocessing. Intervals of positive derivative are shown as dash lines and intervals of non-positive derivative are shown as solid lines.
FIG. 12B exemplifies a saturation signal in which desaturation intervals have been marked based on the derivative signal of FIG. 12A. The desaturation intervals are marked as solid lines while other intervals are marked as dash lines. Several representative desaturation intervals are marked on FIG. 12B by numerals Ia, Ib, 2, 3a, 3b and 4. Intervals Ia and Ib satisfy the unification criteria and are therefore treated as a single interval, referred to hereinunder and in FIGS. 12C-D as interval 1. Likewise, intervals 3a and 3b satisfy the unification criteria and are therefore treated as a single interval, referred to hereinunder and in FIGS. 12C-D as interval 3. . FIG. 12C shows the same derivative signal as FIG. 12B, following an saturation reduction thresholding procedure in which a 3 % saturation reduction threshold is employed. Time intervals identified as corresponding to apnea episodes are shown as
solid lines. All other intervals are shown as dash lines. As shown, interval 4 as well as the unified intervals 1 and 3 (which are the unification of intervals Ia, Ib and 3a, 3b, respectively) are identified as corresponding to apnea episodes. Interval 2 is excluded since its overall desaturation is less than 3 %.. FIG. 12D shows the same derivative signal as FIG. 12B, following an saturation reduction thresholding procedure in which a 4 % saturation reduction threshold is employed. Time intervals identified as corresponding to apnea episodes are shown as solid lines. All other intervals are shown as dash lines. As shown, interval 1 and 4 are identified as corresponding to apnea episodes. Intervals 2 and 3 are excluded since their overall desaturation is less than 4 %..
Processor 32 computes the time shifts between recurrences of features in this binary signal over time in order to detect periodic patterns, which are indicative of periodic breathing. This recurrence function may be computed quickly and simply using logical and shift operations. FIG. 3 is a schematic plot 38 of the recurrence function of a saturation signal as a function of time shift, in accordance with an embodiment of the present invention. The patient in this case was independently diagnosed as suffering from Cheyne-Stokes breathing syndrome. The horizontal axis in FIG. 3 corresponds to time (in minutes) from the beginning of a monitoring session, while the vertical axis represents time shift (in seconds). For each feature (zero-crossing) occurring at a given time on the X-axis, processor 32 searches backward in time for previous occurrences of the same type of feature (ascending or descending). Each point marked in plot 38 indicates a recurrence of the feature of time X at a shift of time Y.
Plot 38 shows a clear pattern of bands 40, meaning that recurrences of features in the saturation signal occurred with a consistent, periodic cycle length (in this case, approximately 67 sec). The inventors have found this band structure to be characteristic of Cheyne-Stokes breathing, with each band corresponding to a different multiple of the cycle length. This sort of plot may be presented by system 20 on display 33 and enables operator 34 to visually diagnose the condition of patient 22. The period and strength of the bands appearing on the display give a good indication of the severity of the patient's condition, which is immediately apparent to the operator.
FIG. 4 is a plot that schematically shows a histogram 44 of the recurrence function of FIG. 3, in accordance with an embodiment of the present invention. The histogram compiles the number of recurrence points in the recording of FIG. 3 as a function of the time shift, and can be seen to comprise multiple bands corresponding to multiples of the basic cycle length. The histogram may likewise be presented on display 33 in order to give the operator another diagnostic indicator.
Additionally or alternatively, processor 32 may fit a parametric model 46 to histogram 44 in order to automatically extract the period and amplitude of the histogram. In various exemplary embodiments of the invention histogram 44 is fitted to an analytical function CS(Δf) representing the probability of finding a pair of features Δf seconds apart. For example, CS(Δf) can be calculated using a set of kernel functions K1 (/ = 1, 2, ..., ή). Preferably, CS(Δf) is calculated a sum, e.g., using the following equation
where w, is the weight of the zth kernel function. The number n of kernel functions in the fit can be predetermined or it can be a free parameter which is selected to optimize the goodness of the fit. In various exemplary embodiments of the invention at least one, more preferably all the kernel functions, is a localized function.
As used herein, "localized function" refers to any function having a local support and which is significantly suppressed far {e.g., at a distance of about 10 widths of the local support) from the local support. Representative examples of localized functions include, without limitation, a Gaussian function, a Lorentzian function, a hyperbolic secant function (also known as sech), a logistic distribution and the like. Additionally, the localized function can be represented as a series or an integral of other functions. For example, the localized function can be a Fourier transform, a wavelet transform and the like.
In embodiments in which the kernel functions are Gaussians, the following expression can be used for the analytical function CS(Δf):
∞, σ(Δ,) =
where, a is an amplitude factor, λ is the average distance between consecutive apneas; σ is the standard deviation of the distance between consecutive apneas, and the summation is taken over multiples / of the average distance λ. The parameters a, λ, σ and optionally n are preferably selected to optimally fit the histogram of distances between features.
As can be seen in FIG. 4, model 46 in this case is strongly periodic, with a cycle length of about 67 sec, and with a high amplitude and low standard deviation (substantially less than the period of the pattern). These features thus give a rapid quantitative assessment of the patient's respiratory conditions. In some embodiments of the present invention processor 32 evaluates the slope of the saturation signal (or of the DC component of the pulse oximeter signal) for each desaturation episode. This is particularly useful for ensuring that the sequences of cyclic breathing episodes are indeed associated with the severity of heart failure status. In central apnea, or when the heart failure state is grave, the slope of the exit from the cycle is moderate, e.g., similar to the typical (or specific) entry slope. Therefore, to identify a time sequence of cyclic breathing as Cheyne-Stokes, processor 32 requires that the sequence comprise mainly (typically at least 80 %) events of moderate slope. (PCT Patent Application PCT/IL2006/000148, the contents of which are hereby incorporated by reference, defines formal criteria for assessing the symmetry of periodic breathing episodes, which may also be used in the present context for distinguishing Cheyne-Stokes events.). The requirement of moderate slope may also be applied to the median slope value.
The observations with respect to the symmetry of the periodic breathing patterns apply both to the slowly-varying heart rate and saturation signals and to the envelopes of the other, rapidly- varying signals shown by the other traces. The term "envelope" in this context typically means a signal derived from the local minima and/or local maxima of another signal, with or without smoothing (by convolution or resampling, for example). "Envelopes" may also be derived by other mathematical operations known in the art, such as application of Hubert transforms. The inventors have found that periodic breathing patterns associated with CSA generally tend to be more symmetrical than the patterns associated with OSA, presumably due to the different physiological mechanisms that are involved in the different types of apneas. Therefore, processor 32
may validate the prognostic value of the Cheyne-Stokes marker by considering only events with mild exit slope from desaturation events. The inventors found that computing the slope of the saturation curve by fitting a line (by the least-square method) to the curve over a nine-second epoch, and requiring that the slope of the line be less then 0.7 percent/second is a good implementation of this mild desaturation condition.
The features of the Cheyne-Stokes segments are prognostic of patient outcome in cases of heart failure (and other illnesses). In particular, long wavelength is associated with bad prognosis. Thus, processor 32 typically detects signal components that have a period greater than a minimum period of at least 30 sec. For example, a periodic breathing pattern is classified as a Cheyne-Stokes breathing if the median cycle length is above 55 seconds and the median desaturation value is at least 2 %. or at least 3 % or at least 4 %.
On the other hand, time segments with steep exit saturation slope typically correspond to obstructive apnea/hypopnea events. Other features of obstructive apnea/hypopnea time segments include short wavelength, large vasomotion, and large heart rate modulations. These phenomena are generally associated with good prognosis, since they reflect the patient's ability to manifest enhanced sympathetic activity.
In addition to the saturation measurements and Cheyne-Stokes detection, processor 32 may also process an AC absorption or reflectance signal that is output by device 24 in order to compute a heart rate, as is known in the art. The AC signal may also be analyzed to detect a beat morphology. The processor can identify certain aberrations in this morphology as arrhythmias, such as premature ventricular contractions (PVCs). The processor optionally keeps a record of the occurrences of such arrhythmias, in a manner similar to a Holter monitor, but without requiring the use of ECG leads. The total number of abnormal heart beats and (specifically PVCs) that are accumulated in such a record, particularly during sleep, is indicative of bad prognosis. As the inventors have found that premature beats during sleep have the greatest prognostic value for advanced heart failure patients, the processor may be configured to count the number of premature beats only during sleep or during episodes of Cheyne-Stokes breathing.
The inventors have found typical Cheyne-Stokes cycle lengths to be between 40 and 90 sec. The cycle length, as well as the other parameters, depends on the severity of
the patient's heart failure. In particular, the inventors have found that decompensated heart failure patients nearly always present long sequences of periodic Cheyne-Stokes breathing episodes, with a cycle length between 55 and 180 seconds. In general, the longer the cycle length, the more severe is the state of the disease. Therefore, processor 32 may use the time characteristics of the patient's Cheyne-Stokes episodes as a prognostic indicator.
FIGS. 5 and 6 are schematic plots of the recurrence function and histogram, respectively, of a saturation signal in another patient, in accordance with an embodiment of the present invention. The patient in this case suffered from more severe heart failure than the patient of FIGS. 3 and 4, and the Cheyne-Stokes bands 40 in FIG. 5 are therefore sharply marked. The severity of the patient's condition is reflected in a highly-periodic histogram 48 of the recurrence function. A parametric curve 50, fitted to histogram 48 using the equation shown above, indicates that the Cheyne-Stokes cycle length in this case is about 82 sec. FIGS. 7 and 8 are schematic plots of the recurrence function and histogram, respectively, of a saturation signal in still another patient, in accordance with an embodiment of the present invention. The patient suffered from obstructive apnea, but not Cheyne-Stokes breathing. As a result, little or no band structure is seen in FIG. 7. A histogram 54 in FIG. 8 does not exhibit any meaningful periodicity, as shown by a parametric curve 56 that is fit to the histogram.
Other types of aberrant waveforms in the photoplethysmograph signal may correspond to motion artifacts. Motion is characterized by local maxima well above normal beat range (for example, at least twice the normal value). The prevalence of motion artifacts can be used in detecting movement, which indicate whether the patient is in a sleep or waking state. Alternatively or additionally, a motion sensor may be used to detect arousals.
Processor 32 may additionally extract other cardiorespiratory parameters from the signal, either directly or indirectly. For example, the processor may apply very-low- frequency filtering to the heart rate in order to detect heart rate modulations. Additionally or alternatively, the envelope of the signal may be processed in order to detect characteristics of vasomodulation, i.e., arterial dilation and constriction.
In some embodiments of the present invention processor 32 computes a respiration energy and/or rate characteristic based on high-frequency components of the signal. Respiratory sinus arrhythmia is a natural cycle of arrhythmia that occurs in healthy people through the influence of breathing on the flow of sympathetic and vagus impulses to the sinoatrial node in the heart. This effect may be used to calculate respiration from heart rate. Well-treated heart failure patients, however, are frequently under the control of cardiac pacemakers and often take beta-blockers and ACE inhibitors that suppress this phenomenon. High-frequency (10-30 cycles/min, i.e., 0.17- 0.5 Hz) filtering of the photoplethysmograph signal enables the processor to determine respiration energy and/or rate characteristics in these cases, as well.
Very-low-frequency components of the characteristic can be indicative of a respiration modulation. Processor 32 can combine the various cardiac, respiratory and vasomodulation parameters described above in order to provide a general picture of cardiorespiratory effects, all on the basis of the photoplethysmograph signals. Similar procedures to those described above can be applied to the detrended AC photoplethysmograph signal. One way to perform detrending is to replace the photoplethysmograph signal with its amplitude feature (maximum minus minimum signal). Other methods include subtracting a polynomial that approximates the signal, or using local maxima or local minima features. Following detrending, the processor applies very-low-frequency filtering followed by outlier rejection, and then computes the median vasomotion of each sequence.
The processor may perform similar analyses on heart rate and respiratory signals from other sources. Arousals can estimated from motion artifacts as described above or from other data if available (such as EEG alpha and beta frequencies, or scorer marking, or a motion sensor).
Information regarding sleep/wake state can be combined with the Cheyne- Stokes time to determine specific, cumulative Cheyne-Stokes time during sleep. The total Cheyne-Stokes time and percentage of Cheyne-Stokes time during sleep have prognostic value: a large percentage of Cheyne-Stokes time is associated with mortality and high levels of brain natriuretic peptide (BNP), which are associated with severity of heart failure. Furthermore, information about sleep time can be used to ensure that low Cheyne-Stokes duration is not associated with little or no sleep.
The information regarding the Cheyne-Stokes time can also be combined with the general picture of cardiorespiratory effects in order to provide some or all of the following combined information for each Cheyne-Stokes sequence during sleep: duration, median wavelength, median desaturation, median vasomotion, median heart rate modulation, median respiratory modulation, number of PVCs and other premature beats, and arousal index (e.g., number of arousals). Each of the above parameters can also be computed separately for REM sleep and NREM sleep.
Clinical Application And Results
The methods described above for measuring and quantifying Cheyne-Stokes breathing and attendant heart failure prognosis provide the physician with a clear, immediate, visual indication of the patient's respiratory condition. They may be used conveniently in performing frequent checks on patient status, both at home and in the hospital. Additionally or alternatively, occasional checks of this sort may be used for risk stratification and screening. As explained above, these methods may be implemented using measurements made solely by pulse oximetry device 24, or alternatively in conjunction with other sensors, as in a multi-monitor polysomnography system, or in an implantable device, or using other types of sensors.
The above-mentioned US 2007/0213622 describes a study in which Cheyne- Stokes breathing characteristics were compared with heart failure status in tests of advanced heart failure patients. This study used the cumulative duration of Cheyne- Stokes breathing during a night's sleep as an indicator, and compared its sensitivity and specificity with measurements of Brain Natriuretic Peptide (BNP) in the patients' blood, which have been generally considered the best marker for heart failure status. The measurement of Cheyne-Stokes duration was found to compare favorably with BNP measurement as a prognostic indicator for heart failure.
The inventors in the present patent application performed a similar clinical study of the efficacy of Cheyne-Stokes cycle length as a prognostic indicator for heart failure. The cycle length (CL) was measured, using the techniques described above and illustrated in FIGS. 3-8, for a group of 109 heart failure patients. The median CL for this patient group was found to be 51 sec. High CL, above the median, was taken as a trial prognostic indicator for the patient group, for comparison with BNP level. The clinical progress of the patients' heart failure was monitored for a six-month period
following the CL and BNP measurements in order to compare the prognostic value of these two indicators.
FIG. 9 is a receiver operating characteristic (ROC) plot, which schematically compares the sensitivity and specificity of BNP and of CL of Cheyne-Stokes breathing in predicting heart failure prognosis, in accordance with an embodiment of the present invention. An upper trace 62 is the ROC curve for Cheyne-Stokes CL>51, while a lower trace 60 is the ROC curve for the BNP marker. To derive the results shown in the figure, both CL and BNP were tested against hospitalization and mortality of the patients over the six-month period of the study. The plot shows that the CL marker gave greater sensitivity and specificity in predicting which patients would be hospitalized or would die during the study period.
FIG. 10 is a Kaplan-Meier plot of a six-month survival function of the heart failure patients as a function of Cheyne Stokes CL, in accordance with an embodiment of the present invention. In this case, patients were classified into two groups: one group with CL>51 , and the other with CL<51. For the purpose of the plots in FIG. 10, the "survival" function corresponds to the number of patients who did not die and were not hospitalized over the study period. An upper trace 68 in the figure shows the survival rate for the group with CL<51, while a lower trace 66 shows the much lower survival rate for patients with CL>51. The plot demonstrates the strength of CL as a prognostic marker.
The results of FIGS. 9 and 10 show that CL measurement based on photoplethysmographic monitoring during sleep may be used effectively for the prognosis of heart failure patients. As explained above, this sort of monitoring is simple to carry out in the patient's home or hospital bed and may be performed at regular intervals, at low cost and minimal discomfort to the patient. It provides physicians with an accurate prognostic indicator, which they can use in choosing the optimal treatment, such as determining whether a patient requires hospitalization, and adjusting treatment parameters (such as drug titration) based on changes in the patient's condition. For example, using the techniques described above, the physician may measure and quantify the patient's symptoms prior to initiating or making a change in treatment, and may repeat the measurement thereafter in order to assess the effectiveness of the treatment and possibly readjust treatment parameters.
As another alternative, the physician may fix a specific critical Cheyne- Stokes CL for individual patients, and then set a monitoring system to alarm whenever this CL is exceeded.
As noted earlier, although the embodiments described above relate mainly to signals captured by pulse oximetry device 24, the principles of the present invention may be applied to respiration signals captured by any other suitable type of sensor.
Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.
EXAMPLES
Reference is now made to the following examples, which together with the above descriptions illustrate some embodiments of the invention in a non limiting fashion.
Prototype System Following is a description of a prototype system which produces sleep analysis.
FIG. 13 depicts a high level block diagram of the prototype system. The block diagram shows sleep analysis from at least one of the following signals: saturation signal, pulse rate, PPG and respiration flow. The system comprises several analysis units. A saturation unit which is responsible of desaturation event detection, Cheyne stokes respiration pattern classification and periodic respiration breathing (PRB).
A Plethysmograph unit which extracts location and magnitude of the PPG. Both are used in order to extract AFIB rhythms, respiratory rate and sleep wake features.
A flow unit for respiratory rate and breath by breath correlation (BBC) as features for sleep wake classification.
A pulse rate unit which calculates pulse rate slope calculation and pulse rate noise extraction for the determination of sleep wake epochs.
A sleep wake classification unit is utilized according to the input data; each feature is associated with probability for sleep and probability for wake and a Viterbi algorithm is performed for sleep wake hypnogram extraction.
A respiratory classification unit, receives hypnogram and desaturation events and classifies highly periodic desaturation events as central sleep apnea and also filter noisy wake desaturation events in order to produce respiratory events.
The saturation unit is further detailed in FIG. 14. The saturation unit can include several sub-units which operate as described above with reference to FIGS. 1 IA-B and
12A-C. The preprocessing subunit performs the preprocessing operation, as further detailed hereinabove, the CumSum subunit calculates and provides the derivative signal as further detailed hereinabove, the Desat Features subunit performs the saturation reduction thresholding procedure as further detailed hereinabove, the unification event subunit unifies intervals over the derivative signal as further detailed hereinabove, and the classification subunit outputs the desaturation features according to their classification.
In order to identify Cheyne Stokes breathing (CSB) of a patient, a collection of start and end points of 10 minutes of, e.g., desaturation 4 % events, are fitted to a parametric model as further detailed hereinabove.
FIG. 15A shows example of saturation during Cheyne Stokes breathing, and FIG. 15B illustrates a parametric model fitting of 10 minutes of the Cheyne Stokes using a Gaussian kernel function. The cycle length is of about 58 seconds.
FIGS. 16A-B present the chaotic effect of obstructive sleep apnea. These features thus give a rapid quantitative assessment of the patient's respiratory conditions.
Once a collection of parameters for the parametric model are obtained, a set of rules are utilized to determine whether a set of apneas are associated with CSB. The rules can be based on the number of periodic desaturation, the width of the standard deviation and the perturbation needed in order to fit the parametric model to the data. Two levels of CSB classification are initiated in case that suspected periodic of
3 % or 4 % detected CSB. In a first level, a set of four highly periodic desaturation events with cycle length in the zone of the average distance between consecutive apneas, are classified as CSB. In a second level a set of seven periodic desaturation events are classified as CSB. The operation of saturation processing is finished once desaturation events, periodic respiratory breathing and Cheyne stokes breathing are extracted and ready to be used in sleep wake classification unit.
Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.
AU publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting.
Claims
1. A method of diagnosis, comprising: receiving a signal associated with respiration of a patient; processing the signal so as to identify features that are indicative of beginning and end times of apnea episodes; computing time shifts between recurrences of the features; processing the time shifts so as to generate an output comprising a plurality of bands corresponding to different multiples of a cycle length of the apnea episodes.
2. The method according to claim 1, wherein the signal is indicative of variations in a blood oxygen saturation in a body of the patient due to the apnea episodes.
3. The method according to claim 2, wherein the signal is received from a photoplethysmographic sensor coupled to the body of the patient.
4. The method according to any of claims 1-3, wherein processing the signal comprises defining a threshold level, and identifying the features as points at which the signal crosses the threshold level.
5. The method according to any of claims 1-3, further comprising extracting the cumulative sum of the first derivative of the signal to provide a derivative signal, wherein said processing comprises extracting slope and duration values from said derivative signal.
6. The method according to any of claims 1-4, wherein processing the time shifts comprises presenting a plot of the bands on a display.
7. The method according to claim 6, wherein presenting the plot comprises displaying the time shifts as a function of time over a monitoring period.
8. The method according to any of claims 1-7, wherein processing the time shifts comprises generating a histogram of the time shifts.
9. The method according to claim 8, wherein processing the time shifts comprises fitting a parametric function to the histogram so as to extract the cycle length from the histogram.
10. The method according to claim 9, wherein the parametric function comprises a sum of kernel functions.
11. The method according to any of claims 1-10, further comprising diagnosing a medical condition of the patient responsively to the cycle length.
12. The method according to claim 11, wherein the medical condition comprises a heart failure of the patient, and wherein diagnosing the medical condition comprises assessing a severity of the heart failure based on the cycle length.
13. The method according to any of claims 1-10, further comprising classifying said apnea episodes to central sleep apnea episodes and obstructive sleep apnea episodes.
14. Apparatus for diagnosis, comprising: a sensor, which is configured to be coupled to a body of a patient and to output a signal associated with associated with respiration of the patient; and a processor, which is coupled to process the signal so as to identify features that are indicative of beginning and end times of apnea episodes, to compute time shifts between recurrences of the features, and to process the time shifts so as to generate an output comprising a plurality of bands corresponding to different multiples of a cycle length of the apnea episodes.
15. The apparatus according to claim 14, wherein the signal is indicative of variations in a blood oxygen saturation in a body of the patient due to the apnea episodes.
16. The apparatus according to claim 15, wherein the sensor comprises a photoplethysmographic sensor.
17. The apparatus according to claim 15, wherein the processor is configured to define a threshold level, and to identify the features as points at which the blood oxygen saturation crosses the threshold level.
18. The apparatus according to claim 14, and comprising a display, wherein the processor is coupled to present a plot of the bands on the display.
19. The apparatus according to claim 18, wherein the plot shows the time shifts as a function of time over a monitoring period.
20. The apparatus according to claim 14, wherein the output comprises a histogram of the time shifts.
21. The apparatus according to claim 20, wherein the processor is configured to fit a parametric function to the histogram so as to extract the cycle length from the histogram.
22. The apparatus according to claim 21, wherein the parametric function comprises a sum of kernel functions.
23. The apparatus according to claim 14, wherein the processor is configured to provide an indication of a severity of a heart failure of the patient based on the cycle length.
24. A computer software product, comprising a computer-readable medium in which program instructions are stored, which instructions, when read by a computer, cause the computer to receive a signal associated with respiration of a patient, to process the signal so as to identify features that are indicative of beginning and end times of apnea episodes, to compute time shifts between recurrences of the features, and to process the time shifts so as to generate an output comprising a plurality of bands corresponding to different multiples of a cycle length of the apnea episodes.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/934,672 US20110054279A1 (en) | 2008-03-27 | 2009-03-25 | Diagnosis of periodic breathing |
EP09726259.6A EP2265176A4 (en) | 2008-03-27 | 2009-03-25 | Diagnosis of periodic breathing |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7232708P | 2008-03-27 | 2008-03-27 | |
US61/072,327 | 2008-03-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009118737A2 true WO2009118737A2 (en) | 2009-10-01 |
WO2009118737A3 WO2009118737A3 (en) | 2010-03-11 |
Family
ID=41114410
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2009/000337 WO2009118737A2 (en) | 2008-03-27 | 2009-03-25 | Diagnosis of periodic breathing |
Country Status (3)
Country | Link |
---|---|
US (1) | US20110054279A1 (en) |
EP (1) | EP2265176A4 (en) |
WO (1) | WO2009118737A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010082200A1 (en) | 2009-01-14 | 2010-07-22 | Widemed Ltd. | Method and system for detecting a respiratory signal |
WO2010121290A1 (en) * | 2009-04-20 | 2010-10-28 | Resmed Ltd | Discrimination of cheyne -stokes breathing patterns by use of oximetry signals |
WO2012085820A1 (en) * | 2010-12-22 | 2012-06-28 | Koninklijke Philips Electronics N.V. | Patient monitoring and exception notification |
CN104640591A (en) * | 2012-01-27 | 2015-05-20 | 瑞思迈有限公司 | Discrimination of cheyne-stokes breathing patterns |
EP2989978A1 (en) | 2014-08-28 | 2016-03-02 | Weinmann Geräte für Medizin GmbH + Co. KG | Artificial respiration device and method for same |
US10512429B2 (en) | 2004-12-23 | 2019-12-24 | ResMed Pty Ltd | Discrimination of cheyne-stokes breathing patterns by use of oximetry signals |
US11896388B2 (en) | 2004-12-23 | 2024-02-13 | ResMed Pty Ltd | Method for detecting and discriminating breathing patterns from respiratory signals |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10335060B1 (en) | 2010-06-19 | 2019-07-02 | Dp Technologies, Inc. | Method and apparatus to provide monitoring |
US9459597B2 (en) | 2012-03-06 | 2016-10-04 | DPTechnologies, Inc. | Method and apparatus to provide an improved sleep experience by selecting an optimal next sleep state for a user |
US10881310B2 (en) | 2012-08-25 | 2021-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Motion artifact mitigation methods and devices for pulse photoplethysmography |
CA2911479A1 (en) * | 2013-05-07 | 2014-11-13 | President And Fellows Of Harvard College | Systems and methods for inhibiting apneic and hypoxic events |
US20150150498A1 (en) * | 2013-12-02 | 2015-06-04 | United Sciences, Llc | Sleep study |
US11963792B1 (en) | 2014-05-04 | 2024-04-23 | Dp Technologies, Inc. | Sleep ecosystem |
US9968293B1 (en) * | 2014-05-16 | 2018-05-15 | Dp Technologies, Inc. | Detecting and estimating sleep stages |
US9931483B2 (en) | 2014-05-28 | 2018-04-03 | Devilbiss Healtcare Llc | Detection of periodic breathing during CPAP therapy |
US11883188B1 (en) | 2015-03-16 | 2024-01-30 | Dp Technologies, Inc. | Sleep surface sensor based sleep analysis system |
US20170049404A1 (en) * | 2015-08-19 | 2017-02-23 | Amiigo, Inc. | Wearable LED Sensor Device Configured to Identify a Wearer's Pulse |
US11844605B2 (en) | 2016-11-10 | 2023-12-19 | The Research Foundation For Suny | System, method and biomarkers for airway obstruction |
US11723579B2 (en) | 2017-09-19 | 2023-08-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
US11478603B2 (en) | 2017-12-31 | 2022-10-25 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
US11452839B2 (en) | 2018-09-14 | 2022-09-27 | Neuroenhancement Lab, LLC | System and method of improving sleep |
US11382534B1 (en) | 2018-10-15 | 2022-07-12 | Dp Technologies, Inc. | Sleep detection and analysis system |
CN110135357B (en) * | 2019-05-17 | 2021-09-21 | 西南大学 | Happiness real-time detection method based on remote sensing |
US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6223064B1 (en) * | 1992-08-19 | 2001-04-24 | Lawrence A. Lynn | Microprocessor system for the simplified diagnosis of sleep apnea |
US6168568B1 (en) * | 1996-10-04 | 2001-01-02 | Karmel Medical Acoustic Technologies Ltd. | Phonopneumograph system |
US6480733B1 (en) * | 1999-11-10 | 2002-11-12 | Pacesetter, Inc. | Method for monitoring heart failure |
US6600949B1 (en) * | 1999-11-10 | 2003-07-29 | Pacesetter, Inc. | Method for monitoring heart failure via respiratory patterns |
US6336903B1 (en) * | 1999-11-16 | 2002-01-08 | Cardiac Intelligence Corp. | Automated collection and analysis patient care system and method for diagnosing and monitoring congestive heart failure and outcomes thereof |
US7806831B2 (en) * | 2000-03-02 | 2010-10-05 | Itamar Medical Ltd. | Method and apparatus for the non-invasive detection of particular sleep-state conditions by monitoring the peripheral vascular system |
US6839581B1 (en) * | 2000-04-10 | 2005-01-04 | The Research Foundation Of State University Of New York | Method for detecting Cheyne-Stokes respiration in patients with congestive heart failure |
US6589188B1 (en) * | 2000-05-05 | 2003-07-08 | Pacesetter, Inc. | Method for monitoring heart failure via respiratory patterns |
US6454719B1 (en) * | 2000-08-01 | 2002-09-24 | Pacesetter, Inc. | Apparatus and method for diagnosis of cardiac disease using a respiration monitor |
WO2002054951A2 (en) * | 2001-01-12 | 2002-07-18 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Decoding algorithm for neuronal responses |
US6641542B2 (en) * | 2001-04-30 | 2003-11-04 | Medtronic, Inc. | Method and apparatus to detect and treat sleep respiratory events |
US6709402B2 (en) * | 2002-02-22 | 2004-03-23 | Datex-Ohmeda, Inc. | Apparatus and method for monitoring respiration with a pulse oximeter |
US7160252B2 (en) * | 2003-01-10 | 2007-01-09 | Medtronic, Inc. | Method and apparatus for detecting respiratory disturbances |
US7524292B2 (en) * | 2003-04-21 | 2009-04-28 | Medtronic, Inc. | Method and apparatus for detecting respiratory disturbances |
US8467876B2 (en) * | 2003-10-15 | 2013-06-18 | Rmx, Llc | Breathing disorder detection and therapy delivery device and method |
WO2005037355A1 (en) * | 2003-10-17 | 2005-04-28 | Resmed Limited | Methods and apparatus for heart failure treatment |
US7070568B1 (en) * | 2004-03-02 | 2006-07-04 | Pacesetter, Inc. | System and method for diagnosing and tracking congestive heart failure based on the periodicity of Cheyne-Stokes Respiration using an implantable medical device |
US7413549B1 (en) * | 2004-03-17 | 2008-08-19 | Pacesetter, Inc. | Detecting and quantifying apnea using ventilatory cycle histograms |
US7371220B1 (en) * | 2004-06-30 | 2008-05-13 | Pacesetter, Inc. | System and method for real-time apnea/hypopnea detection using an implantable medical system |
US7578793B2 (en) * | 2004-11-22 | 2009-08-25 | Widemed Ltd. | Sleep staging based on cardio-respiratory signals |
EP2377462A3 (en) * | 2004-12-23 | 2012-01-11 | ResMed Ltd. | Apparatus for detecting and discriminating breathing patterns from respiratory signals |
US7704211B1 (en) * | 2005-03-21 | 2010-04-27 | Pacesetter, Inc. | Method and apparatus for assessing fluid level in lungs |
US8992436B2 (en) * | 2005-09-16 | 2015-03-31 | Cardiac Pacemakers, Inc. | Respiration monitoring using respiration rate variability |
US7766840B2 (en) * | 2005-12-01 | 2010-08-03 | Cardiac Pacemakers, Inc. | Method and system for heart failure status evaluation based on a disordered breathing index |
US7896813B2 (en) * | 2006-03-31 | 2011-03-01 | Medtronic, Inc. | System and method for monitoring periodic breathing associated with heart failure |
US8475387B2 (en) * | 2006-06-20 | 2013-07-02 | Adidas Ag | Automatic and ambulatory monitoring of congestive heart failure patients |
EP2091428A4 (en) * | 2006-09-07 | 2012-05-30 | Widemed Ltd | Detection of heart failure using a photoplethysmograph |
US20090326867A1 (en) * | 2008-06-30 | 2009-12-31 | Nellcor Puritan Bennett Ireland | Signal processing systems and methods for determining slopes of electronic signals |
-
2009
- 2009-03-25 EP EP09726259.6A patent/EP2265176A4/en not_active Withdrawn
- 2009-03-25 WO PCT/IL2009/000337 patent/WO2009118737A2/en active Application Filing
- 2009-03-25 US US12/934,672 patent/US20110054279A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of EP2265176A4 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11896388B2 (en) | 2004-12-23 | 2024-02-13 | ResMed Pty Ltd | Method for detecting and discriminating breathing patterns from respiratory signals |
US10512429B2 (en) | 2004-12-23 | 2019-12-24 | ResMed Pty Ltd | Discrimination of cheyne-stokes breathing patterns by use of oximetry signals |
US9351665B2 (en) | 2009-01-14 | 2016-05-31 | Widemed Technologies Ltd. | Method and system for detecting a respiratory signal |
WO2010082200A1 (en) | 2009-01-14 | 2010-07-22 | Widemed Ltd. | Method and system for detecting a respiratory signal |
CN104757975B (en) * | 2009-04-20 | 2017-12-05 | 瑞思迈有限公司 | Tidal breathing pattern is distinguished using oxygen saturation signal |
CN104757975A (en) * | 2009-04-20 | 2015-07-08 | 瑞思迈有限公司 | Discrimination of cheyne -stokes breathing patterns by use of oximetry signals |
WO2010121290A1 (en) * | 2009-04-20 | 2010-10-28 | Resmed Ltd | Discrimination of cheyne -stokes breathing patterns by use of oximetry signals |
US9901287B2 (en) | 2010-12-22 | 2018-02-27 | Koninklijke Philips N.V. | Patient monitoring and exception notification |
WO2012085820A1 (en) * | 2010-12-22 | 2012-06-28 | Koninklijke Philips Electronics N.V. | Patient monitoring and exception notification |
CN104640591A (en) * | 2012-01-27 | 2015-05-20 | 瑞思迈有限公司 | Discrimination of cheyne-stokes breathing patterns |
US10863949B2 (en) | 2012-01-27 | 2020-12-15 | ResMed Pty Ltd | Discrimination of cheyne-stokes breathing patterns |
US11992344B2 (en) | 2012-01-27 | 2024-05-28 | ResMed Pty Ltd | Discrimination of cheyne stokes breathing patterns |
EP2989978A1 (en) | 2014-08-28 | 2016-03-02 | Weinmann Geräte für Medizin GmbH + Co. KG | Artificial respiration device and method for same |
DE102015009056A1 (en) | 2014-08-28 | 2016-03-03 | Weinmann Geräte für Medizin GmbH + Co. KG | Respirator and procedure for a ventilator |
US10159810B2 (en) | 2014-08-28 | 2018-12-25 | Loewenstein Medical Technology S.A. | Respiration device and method for a respiration device |
US11602604B2 (en) | 2014-08-28 | 2023-03-14 | Loewenstein Medical Technology S.A. | Respiration device and method for a respiration device |
US12053581B2 (en) | 2014-08-28 | 2024-08-06 | Loewenstein Medical Technology S.A. | Respiration device and method for a respiration device |
Also Published As
Publication number | Publication date |
---|---|
US20110054279A1 (en) | 2011-03-03 |
WO2009118737A3 (en) | 2010-03-11 |
EP2265176A4 (en) | 2014-01-29 |
EP2265176A2 (en) | 2010-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110054279A1 (en) | Diagnosis of periodic breathing | |
US7803119B2 (en) | Respiration-based prognosis of heart disease | |
Dash et al. | Estimation of respiratory rate from ECG, photoplethysmogram, and piezoelectric pulse transducer signals: a comparative study of time–frequency methods | |
US8485978B2 (en) | Systems and methods for noninvasively monitoring baroreflex response and nominal blood volume | |
CN109310347B (en) | Method and apparatus for non-invasive detection of physiological and pathophysiological sleep conditions | |
EP1711104B1 (en) | Method and apparatus for ecg-derived sleep disordered breathing monitoring, detection and classification | |
JP5281002B2 (en) | Portable automated monitoring of patients with congestive heart failure | |
JP5303802B2 (en) | Apnea / hypopnea index derived from ECG | |
Phan et al. | Estimation of respiratory waveform and heart rate using an accelerometer | |
US8668649B2 (en) | System for cardiac status determination | |
US20080269583A1 (en) | Detection and Monitoring of Stress Events During Sleep | |
US10278595B2 (en) | Analysis and characterization of patient signals | |
US20050148895A1 (en) | Method and apparatus for ECG derived sleep monitoring of a user | |
WO2008029399A2 (en) | Detection of heart failure using a photoplethysmograph | |
JP2021517008A (en) | Sleep apnea detection system and method | |
US20200359909A1 (en) | Monitoring device including vital signals to identify an infection and/or candidates for autonomic neuromodulation therapy | |
US10327648B2 (en) | Blood vessel mechanical signal analysis | |
US9402571B2 (en) | Biological tissue function analysis | |
Leier et al. | Respiration signal extraction from photoplethysmogram using pulse wave amplitude variation | |
Ahmed et al. | PPG signal morphology-based method for distinguishing stress and non-stress conditions | |
Dehkordi et al. | Sleep/wake classification using cardiorespiratory features extracted from photoplethysmogram | |
Wolling et al. | Optimal preprocessing of raw signals from reflective mode photoplethysmography in wearable devices | |
US20190343442A1 (en) | System and method to determine heart rate variability coherence index | |
Zaretskiy et al. | Robust heart rate estimation using combined ECG and PPG signal processing | |
Selvaraj et al. | Time-varying methods for characterizing nonstationary dynamics of physiological systems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09726259 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009726259 Country of ref document: EP |